Your Partner for Expert Advice for Nonclinical Development and Clinical Pharmacology for Human Therapeutics
Founded in 2004 by ex-FDA regulators, Aclairo PDG is committed to delivering independent and objective advice and guidance to the pharmaceutical industry in the areas of nonclinical pharmacology, toxicology, ADME, and clinical pharmacology. Our consultants, composed of former FDA supervisors/reviewers and industry veterans, have over 350 years of combined drug development experience. Aclairo is a wholly owned subsidiary of Experimental Pathology Laboratories, a private, employee-owned company. Combined, we have become industry and government’s premier source for expert toxicologic pathology evaluation and consultation.
Aclairo is universally known for providing superior technical expertise to its clients including generation of the highest quality analysis, guidance documents, opinions, reports and regulatory submissions in both a timely, and cost-effective manner for hundreds of drug candidates. Our expertise goes well beyond that which is listed below.
Our expertise goes beyond what’s listed.
Expert Support for Your Drug Development Goals
Backed by decades of hands-on experience in nonclinical and clinical drug development, regulatory strategy, DMPK, and Clinical Pharmacology, Aclairo delivers expert guidance and meaningful insights to pharmaceutical and biotech organizations throughout the entire drug development cycle. We focus on understanding each client’s goals to develop targeted solutions for their specific challenges.
Trusted, Independent Expertise. Committed to Your Success.
From pharmacology to toxicology, our experts provide responsive, senior-level support at every phase with the unique ability to combine strategic insight with hands-on experience in drug development.
Latest News
Advancing Treg Cell Therapy
Uyen Dinh, PhD and I were delighted to be asked to contribute to a special
SOT 65th Annual Meeting
EPL and Aclairo Pharmaceutical Development Group, Inc. are looking forward to seeing everyone at the
FDA Gene Editing Guidance
FDA has issued a new gene editing guidance that gives additional information on expectations for
Regulatory Guidance
Start the conversation now.